LLY, CORZ & FGF: Honest 2026 Analysis of Market Shifts

# Market Health and Biotech Growth: A Clear Guide to LLY, CORZ, and FGF Developments  Understanding the complex landscape of global markets requires a steady hand and a focus on long-term fundamentals. Today, we examine three significant developments that have reshaped investor expectations: the financial results of pharmaceutical giant Eli Lilly, a rejected merger proposal for Core Scientific, and a bold strategic pivot from Fundamental Global Inc. These updates provide a data-driven look at how industry leaders are adapting to new economic environments. ## Eli Lilly’s Metabolic Growth: Assessing the Vitals of a Pharma Leader  Eli Lilly (LLY) recently shared its second-quarter 2025 financial results, revealing a period of significant growth. Total revenue reached $15.56 billion, a 38% increase compared to the same period in the previous year, as detailed in their [financial results](https://coincentral.com/eli-lilly-lly-stock-drops-14-despite-38-revenue-growth-led-by-zepbound-and-mounjaro/22025-08-08). This surge was primarily fueled by the strong performance of Lilly's diabetes and obesity treatments, Mounjaro and Zepbound. ### The Impact of Zepbound and Mounjaro Demand for these GLP-1 and GIP dual agonist medications has been robust. In the U.S. alone, Zepbound revenue soared by 172% to $3.38 billion, while Mounjaro's global revenue increased by 68%, reaching $5.20 billion, according to the company's [official earnings release](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2025-financial-results-and-raises). These figures reflect a global shift in the approach to cardiometabolic health. The volume of demand is the primary driver here. Lilly reported a 42% increase in total volume, which successfully balanced out a 6% decline in realized prices, as noted in their [financial results](https://coincentral.com/eli-lilly-lly-stock-drops-14-despite-38-revenue-growth-led-by-zepbound-and-mounjaro/22025-08-08). This indicates that while the cost per dose might be facing downward pressure due to payer rebates and competitive access, the number of patients seeking these treatments continues to climb. ### A Surprising Market Reaction Despite these strong results and management raising the full-year 2025 revenue guidance to a range of $60 billion to $62 billion, the stock faced a sharp decline, as [analysis from Nasdaq](https://www.nasdaq.com/articles/eli-lilly-lly-q2-revenue-jumps-38) highlighted. On August 7, 2025, Eli Lilly shares plunged 14.14%, closing at $640.86. Here are some factors to consider regarding this decline: 1. **Profit-Taking**: After a long and sustained rally, many investors chose to realize gains following the earnings report. 2. **Tax Adjustments**: The market reacted to a projected 2025 effective tax rate of 19%, an increase tied to recent changes in U.S. tax legislation. 3. **Formulary Challenges**: Management noted that some pharmacy benefit managers (PBMs), such as CVS Caremark, have made decisions that could limit access to Zepbound in favor of competitors, creating uncertainty for forward-looking projections, as discussed in both the [Nasdaq analysis](https://www.nasdaq.com/articles/eli-lilly-lly-q2-revenue-jumps-38) and a [Q1 2025 earnings summary](https://fintool.com/app/research/companies/LLY/earnings/Q1%202025). ### Long-Term Research and Development Looking ahead, Lilly is not resting on its current success. The company’s R&D spending increased by 23% to $3.34 billion. They are currently monitoring the progress of orforglipron, an oral treatment for obesity that could offer a more convenient option for patients, as noted in a [Q1 2025 earnings summary](https://fintool.com/app/research/companies/LLY/earnings/Q1%202025). Additionally, Kisunla (donanemab) has received marketing authorization in several regions for the treatment of early symptomatic Alzheimer’s disease, adding another layer of diversity to the company's portfolio, a development that has contributed to a [brightened outlook for the company](https://www.investing.com/analysis/eli-lilly-outlook-brightens-with-fda-wins-and-global-expansion-in-manufacturing-200669375). ## Core Scientific and the Proposed Merger: A Case of Undervaluation? A proposed $9 billion merger between Core Scientific (CORZ) and CoreWeave has met with significant resistance from shareholders who believe the deal undervalues the company, as [reported in detail](https://coincentral.com/core-scientific-shareholders-rejects-9-billion-merger-with-coreweave/12025-08-07). ### The Shareholder Revolt Two Seas Capital LP, which holds more than 6% of Core Scientific’s shares, has formally opposed the all-stock sale, as [reported in detail](https://coincentral.com/core-scientific-shareholders-rejects-9-billion-merger-with-coreweave/12025-08-07). In a detailed open letter, the firm argued that the merger terms are fundamentally unfair. Under the proposed agreement, Core Scientific shareholders would receive 0.1235 CoreWeave shares for each CORZ share they own, according to the [report on the shareholder rejection](https://coincentral.com/core-scientific-shareholders-rejects-9-billion-merger-with-coreweave/12025-08-07). While this appeared to offer a 66% premium at the time of the June announcement, Two Seas argues that the uncollared structure of the deal is a significant risk factor. Without price protections, shareholders are exposed to the volatility of CoreWeave’s stock. ### Strategic Infrastructure vs. Mining CoreWeave’s primary interest lies in Core Scientific’s 1.3 GW of power capacity. They aim to repurpose these facilities for AI workloads. However, the opposition believes that Core Scientific’s assets are uniquely positioned for the AI era and that the company can thrive through independent expansion rather than a merger. Key concerns raised by the largest active shareholder include: * **Ownership Stakes**: The deal would leave current shareholders with less than 10% ownership of the combined entity. * **Asset Value**: The transaction may significantly undervalue the long-term potential of the company’s compute and energy infrastructure. * **Market Sentiment**: Following the announcement of the opposition, CORZ shares saw a slight rebound, suggesting other investors share these concerns. ## Fundamental Global Inc.: A Bold Pivot to Digital Assets Fundamental Global Inc. (FGF) recently filed a major S-3 registration with the SEC to offer up to $5 billion in securities, signaling a significant strategic shift, as [revealed in their SEC filing](https://coincentral.com/fundamental-global-inc-fgf-stock-surge-over-5-as-5b-sec-filing-reveals-bold-ethereum-acquisition-plan/22025-08-07). ### The Ethereum Strategy What makes this filing particularly noteworthy is the intended use of the proceeds. FGF has disclosed that the bulk of the capital raised will be used to fund direct acquisitions of Ethereum (ETH), a [bold plan revealed in their SEC filing](https://coincentral.com/fundamental-global-inc-fgf-stock-surge-over-5-as-5b-sec-filing-reveals-bold-ethereum-acquisition-plan/22025-08-07). This represents a significant pivot for a traditionally non-crypto firm. Here is how the $5 billion strategy is structured: 1. **Flexibility**: The company can issue common stock, preferred shares, debt securities, or warrants in multiple tranches. 2. **At-the-Market (ATM) Agreement**: Up to $4 billion of the total can be issued as common stock through an agreement with ThinkEquity, LLC. 3. **Operational Support**: While Ethereum is the primary target, the remaining funds will support working capital and general corporate needs. ### Regulatory Boundaries and Limits While the $5 billion figure is headline-grabbing, it is important to understand the regulatory limits. Because FGF’s public float is currently below the $75 million threshold—sitting at approximately $32 million as of early August 2025—it is subject to General Instruction I.B.6 of Form S-3. This means the company cannot exceed $10.67 million in primary offerings within any 12-month period as long as its market value remains at these levels. However, if the stock price increases and the market cap grows, these limits could be lifted. Investors reacted positively to the strategy, with shares jumping 3.76% in after-hours trading following the filing, as [reported following the SEC filing](https://coincentral.com/fundamental-global-inc-fgf-stock-surge-over-5-as-5b-sec-filing-reveals-bold-ethereum-acquisition-plan/22025-08-07). ## Summarizing Market Vitality As we review these developments, several patterns emerge. Success in the current market requires a balance of innovation and stable execution. * **Eli Lilly** remains a powerhouse in metabolic health, though it must navigate market challenges such as shifting tax laws and PBM restrictions. * **Core Scientific** finds itself at a crossroads, where shareholders are demanding a better valuation than the currently proposed merger offers. * **Fundamental Global Inc.** is attempting a transformative shift by integrating digital assets into its core financial strategy. | Company | Key Development | Market Sentiment | | :--- | :--- | :--- | | **Eli Lilly** | 38-54% Revenue Growth; Stock Sell-off | Reassuring fundamentals, cautious pricing | | **Core Scientific** | $9B Merger Rejection | Shareholder-led demand for higher value | | **Fundamental Global** | $5B Ethereum Acquisition Plan | Optimistic reaction to bold crypto pivot | It is important to consult with a financial advisor or licensed market professional before making any significant investment decisions. Always ensure you have a balanced view of the risks and rewards.